Reta40

Description

Retatrutide Peptide Overview

Retatrutide (LY3437943) is a first-in-class single-molecule triple agonist that activates the GIP, GLP-1 and glucagon receptors. This combined incretin-and-glucagon signaling makes it one of the most actively studied compounds in metabolic and energy-expenditure research.

Triple Receptor Activation

Retatrutide simultaneously engages three metabolic receptors — GIP, GLP-1 and glucagon. Research explores how this combination influences insulin secretion, glucose regulation and, through the glucagon component, energy expenditure in experimental models.

Glucagon-Driven Energy Expenditure

The addition of glucagon-receptor activity distinguishes retatrutide from dual agonists. In research models, glucagon signaling is studied for its role in increasing energy expenditure and influencing lipid metabolism.

Appetite and Metabolic Regulation

As with other incretin peptides, retatrutide is studied for its effects on central appetite pathways and overall metabolic balance.

Extended Half-Life Design

Retatrutide incorporates modifications that extend its duration of action, a subject of ongoing pharmacokinetic research.

Specifications

• CAS Number: 2381089-83-2
• Molecular Formula: C221H342N46O68 (as reported)
• Molar Mass: approx. 4731 g/mol
• Class: Triple GIP / GLP-1 / glucagon receptor agonist (peptide)
• Storage: Refrigerate after reconstitution.
• Form: Lyophilized powder in a sterile glass vial.
• Purity: Minimum 99%
• Quantity: 40mg per vial
• Color: White

Important Note: This product is intended solely for in vitro laboratory research by licensed professionals. It is not approved by the FDA for human or animal use and should not be misbranded, misused, or mislabeled as a drug, food, supplement, or cosmetic.

References:

1. Coskun T. et al. – LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist – Cell Metabolism
2. Jastreboff A.M. et al. – Triple-hormone-receptor agonist retatrutide for obesity – New England Journal of Medicine
3. Rosenstock J. et al. – Retatrutide in type 2 diabetes – The Lancet
4. Glucagon receptor signaling and energy expenditure – Molecular Metabolism